Apr 30, 2026 08:00AM
Apr 15, 2026 08:00AM
Apr 15, 2026 08:00AM
Aug 5, 2025 08:01AM
Aug 5, 2025 08:00AM
May 27, 2025 08:04AM
May 27, 2025 08:00AM Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 15, 2025 08:01AM
May 15, 2025 08:00AM
May 5, 2025 08:00AM
Apr 29, 2025 08:00AM
Jul 22, 2024 08:07AM
Jul 11, 2024 06:40PM
Jun 2, 2024 08:56PM Immutep (IMM) Announces Clinical Collaboration with MSD
Jun 2, 2024 08:38PM
Dec 21, 2023 08:06AM
Aug 3, 2023 06:05AM
Aug 1, 2023 08:00AM
Jul 31, 2023 08:00AM
Jul 31, 2023 08:00AM
Jul 28, 2023 08:00AM First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Jun 27, 2023 08:00AM
Jun 5, 2023 08:00AM
May 26, 2023 08:00AM
May 26, 2023 08:00AM
May 25, 2023 08:00AM
May 24, 2023 08:00AM
May 16, 2023 08:01AM Immutep (IMMP) Receives Positive Feedback from FDA on Eftilagimod Alpha
May 16, 2023 08:00AM
May 2, 2023 08:00AM
May 1, 2023 08:00AM
Apr 27, 2023 08:00AM
Apr 17, 2023 09:00AM
Mar 31, 2023 08:01AM
Mar 31, 2023 08:00AM Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Mar 30, 2023 08:00AM
Mar 14, 2023 08:00AM
Jan 30, 2023 08:00AM
Jan 4, 2023 08:00AM
Dec 23, 2022 08:00AM
Dec 23, 2022 08:00AM
Dec 8, 2022 08:00AM Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Nov 29, 2022 08:00AM
Nov 10, 2022 11:11AM
Nov 10, 2022 11:10AM
Nov 10, 2022 09:00AM
Nov 9, 2022 08:00AM
Nov 4, 2022 08:00AM
Nov 2, 2022 08:00AM Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Oct 26, 2022 08:00AM

322,899 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All